|
Jun 12
|
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
|
|
Jun 12
|
Ionis doses first subject in Phase III trial of Angelman syndrome therapy
|
|
Apr 16
|
Ionis to hold first quarter 2025 financial results webcast
|
|
Mar 12
|
Ono earmarks $940m to gain rare blood cancer therapy from Ionis
|
|
Mar 12
|
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal
|
|
Mar 12
|
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
|
|
Mar 12
|
Ono pays $280M to license Ionis rare disease drug
|
|
Mar 11
|
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
|
|
Mar 11
|
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
|
|
Mar 10
|
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
|
|
Feb 27
|
Theratechnologies Inc (THTX) Q4 2024 Earnings Call Highlights: Strong EBITDA Turnaround and ...
|
|
Oct 9
|
Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds
|
|
Oct 8
|
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
|
|
Jul 25
|
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 23
|
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
|
|
Jul 23
|
Ionis Pharmaceuticals reports data from Phase I/II trial of Angelman syndrome drug
|
|
Jun 19
|
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
|
|
Jun 18
|
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
|
|
Jan 23
|
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
|
|
Jan 22
|
UPDATE 2-Ionis Pharma's genetic disease drug succeeds in late-stage study
|